Veozah (fezolinetant) was approved in 2023 by the FDA to treat moderate to severe hot flashes. A similar drug, elinzanetant, ...

A diet that replaces animal products with plant-based foods—whether unprocessed or ultra-processed—and includes soybeans can ...

Related: 3 Weird Menopause Signs No One's Talking About. Why Are They Worse When It’s Hot Out? Hot flashes are worse in the summer because—well, you’re already hot. “In th ...

Astellas’ drug, Veozah ... FDA said the medication will provide “an additional safe and effective treatment option for women.” More than 80% of women experience hot flashes during menopause ...

Menopause and the 7-14 years that precede it known as perimenopause affect every woman as they age. When this happens, a range of symptoms occur that may include difficulty sleeping, pain during ...

The U.S. Food and Drug Administration (FDA) has issued its most serious warning -- a black-box warning -- for Veozah, a medication used to relieve hot flashes in menopausal women, due to rare but ...

Veozah was approved in 2023. At the time, it was the first non-hormonal prescription option for treating hot flashes. The medication works by blocking neurokinin B, a receptor involved in the ...

Veozah is an oral, neurokinin 3 receptor antagonist indicated for the treatment of moderate to severe vasomotor symptoms due to menopause. The labeling for the product now includes a boxed warning ...

The FDA has issued a black-box warning for Veozah, a hot-flash medication, due to rare but serious liver risks Regular liver testing is recommended during Veozah treatment to ensure early ...

a nonhormonal medication indicated for treating menopausal hot flashes, according to an agency press release. The boxed warning, the FDA’s most prominent warning, follows a notice the agency ...

Astellas Pharma Canada, Inc. is proud to announce the Health Canada approval of Veozah ... to severe VMS (hot flashes and night sweats) associated with menopause. This safe and effective non-hormonal ...